Paratuberculosis

LOS ANGELES--(BUSINESS WIRE)-- Auckland-based biotechnology company Pictor Limited has been developing an accurate, affordable multiplexed diagnostic test for Mycobacterium avium paratuberculosis (MAP) – also known as Johne’s disease, that could save the New Zealand dairy industry upwards of $80 million a year in lost production. “The PictArray™ MAP assay would be a positive addition to national control programs to help in the eradication of Johne’s disease from the dairy industry,” says Pictor’s Director of Research and Development, Dr. Natasha Gordon, who will be presenting at a Johne’s disease conference this week in Dublin, Ireland. The PictArray multiplex enzyme-linked immunosorbent assay (ELISA) technology allows multiple biomarkers to be tested in a single well. This feature increases the information gained by the clinical testing laboratory, enabling improved disease management on the farm. Conventional ELISA takes a snapshot of a disease at one moment in time, while the PictArray multiplex allows complex diseases to be monitored through different stages of infection using biomarkers that present at different time points during the infection cycle, including asymptomatic stages. Earlier detection of Johne’s disease would allow infected animals to be removed from herds sooner, minimizing transmission. “Our PictArray MAP assay could facilitate improved biosecurity, and support trade, because tests can be performed quickly and accurately when importing, exporting or moving livestock and associated products between local locations, resulting in safe transportation without the risk of spreading infection,” says Gordon. The research project is led by Pictor in a collaboration with Dr Rao Dukkipati, senior lecturer at Massey University, and builds on long-term research at Massey University by Associate Professor Alan Murray. Pictor received a $404,040 grant from the New Zealand Government’s Ministry for Primary Industries’ Sustainable Food and Fibre Futures fund to develop the test and Pictor has filed a PCT application for this multiplexed assay. About Pictor Pictor is an in vitro diagnostics company that offers a patented multiplexed platform for highly accurate and efficient testing of complex and infectious diseases for human and animal health. PictArray™ multiplexed technology makes it possible to test multiple disease markers in a single test simultaneously — with higher sensitivity, faster throughput, and reduced turn-around time. The company’s lead product, PictArray™ SARS-CoV-2 IgG ELISA Kit, enables more informed clinical intervention to manage the threat of COVID-19. For more information, please visit , , and @PictorLtd on Twitter. About Massey University Established in 1927 and located in Palmerston North, New Zealand, Massey University offers internationally recognised teaching and research. The School of Agriculture and Environment – Te Kura Mātauranga mō Ahuwhenua me Te Taiao aims to develop a balance between social, environmental, and economic outcomes for production and sustainability. View source version on businesswire.com: Contacts Business/Sales Contact Howard Moore h.moore@pictordx.com Source: Pictor View this news release online at:

WESTMINSTER, Colo., April 27, 2021 (GLOBE NEWSWIRE) -- GeneThera, Inc. announced today that it has entered into a partnership agreement with Cumming Corporation, a privately held international project consulting firm, specialized in the healthcare sector company. The partnership with Cumming Corporation will allow GeneThera to implement its strategy to build a global network of laboratories designed to prevent control and treat present and future pandemics. The designing of specialized, high safety level laboratory facilities has become a critical supporting component in the fight against present and future pandemics. The SARS-CoV-2 virus has changed the way life-science laboratories are designed and built. The partnership between GeneThera, Inc. and Cumming Corporation represents the first example of a multi comprehensive zoonotic diseases targeted laboratory facilities. GeneThera laboratory facilities will be divided into five laboratory areas: Genome Sequencing Molecular Robotics and AI based Q-PCR diagnostics Viral Molecular Therapeutics (CRISPR-Cas-13) Technology Support Facility to Mobile Laboratories Biosafety Level 3 (BSL) Viral Growth Facility Dr. Tony Milici, Chairman and CEO of GeneThera, Inc. (OTC: GTHR) stated; “We are extremely thrilled to partner with Cumming. This is a gigantic step forward for the realization of GeneThera’s Zoonotic Diseases Alert Shield System (ZIDAS) and its related technology. Thanks to the expertise and support of Cumming, we will be able to implement and expand our business model and technology platform more quickly and efficiently. Our laboratory facility in Colorado will be the first step for the creation and implementation of the ZIDAS platform both nationally and internationally. Cumming expertise and knowledge in laboratory design will provide GeneThera with the necessary tools to achieve its goal of creating a network of labs dedicated to diagnostic and therapeutic of zoonotic diseases using standardized state-of-the-art technology. As previously stated, technology standardization is absolutely vital to successfully predict control and treat pandemics. One of the lessons we must learn from the COVID-19 pandemic is that without standardized laboratory protocols and facilities, we will never be able to successfully be ahead of pandemic-causing viruses now and in the future.” "We are very excited to partner with the team over at GeneThera, Inc. to help build laboratories that will provide safe and efficient diagnostic environments while resetting facility standards for future infectious disease research," said Jack Christensen, director at Cumming. "Being able to leverage all of the specialized knowledge of Cumming's nationwide life-sciences team allows us to implement much-needed lessons learned in lab design, space, and construction requirements from the current pandemic to deliver the next generation of laboratory environments." About GeneThera, Inc. GeneThera is a biotechnology company developing molecular robotic/AI diagnostics and therapeutics in an effort to control and eradicate zoonotic diseases. GeneThera developed molecular assays for BSE and Mycobacterium Avium Paratuberculosis (MAP). MAP is an infectious organism causing Paratuberculosis in dairy cows that is also linked to Crohn’s Disease in humans. We utilize these technologies to minimize the spread of animal infectious organisms such as SARS-CoV-2 to humans. Management and prevention of zoonotic diseases is crucial to human and animal health on a global scale. About Cumming Cumming is an international project and cost management firm with 30 domestic and five international offices, and approximately 1,000 team members. Since opening for business in 1996, Cumming has provided efficient and cost-effective solutions to ensure that projects in the commercial, hospitality, retail, entertainment, education, healthcare, and high-end residential sectors are executed on time and within budget. Cumming provides a solutions-oriented suite of services that specifically addresses its clients' unique challenges, thus enabling them to achieve extraordinary results. For more information, please visit . This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release. For further information, please contact: Tony Milici MD, PhD GeneThera, Inc. (720) 587-5100

WESTMINSTER, Colo., April 13, 2021 (GLOBE NEWSWIRE) -- We are developing the infrastructure of a global zoonotic infectious diseases “alert shield” (ZIDAS) able to successfully manage and control the COVID-19 pandemic; and ultimately prevent future pandemics from developing. This alert shield will operate like a “nuclear shield,” designed to detect incoming nuclear warheads and destroy them before they can be deployed. A global network of AI controlled laboratory robotic systems, capable of collecting, storing and analyzing data, will be able to perform such a task. We envision two types of laboratory settings: The first, stationary integrated robotic lab facilities designed for ultra high throughput, capable to processing 100,000-200,000 samples/lab/day. Samples will be collected from the general population and sent to the labs to be tested. These facilities will be also focus on growing viral strains for R&D and new anti-viral therapeutics development for SARS-CoV-2 and other potential pandemic viruses Mobile integrated robotic lab units will be designed as a scaled- down version of the ultra-high throughput platform described above. Each mobile unit will be equipped with an integrated robotic system capable to perform 2,000-4,000 samples/units/day. Electric vehicles represent the ideal solution to the development of this network of mobile labs designed to test wastewater from reclamation plants. Dr. Tony Milici, Chairman & CEO of GeneThera (OTC: GTHR), commented: “We believe that the implementation of SMART TESTING TECHNOLOGY (STT) could change the course of the COVID pandemic and predict future pandemic before they developed. It is quite clear that performing massive number of testing using unreliable or non standardized technology does not control the virus or provide scientists the information needed to understand the spread of the virus and the insurgence of new potentially dangerous strains. It is still unclear whether or not vaccines will be able to stop the COVID. Additionally mass vaccination is creating a false sense of safety within the general population in part due widespread media misinformation among other variables. As result, the number of tests being performed is declining. Consequentially wastewater testing has became even more important to detect the rate of viral infection in the human population and specific communities. Presently most diagnostic and university labs are only capable of processing a low number of wastewater samples daily. GeneThera’s plan to deploy mobile robotic laboratories units capable of processing on location, thousand of wastewater samples using Smart Testing Technology will be a critical component of our ZIDAS surveillance system platform. This technology should be able to analyze the spread of the virus within communities and discover the presence of new viral variances before they would infect the general population. Our ultimate goal is to deploy tens of thousands of mobile lab units capable of processing thousand of samples worldwide using vehicles that can last for decades with extraordinary little maintenance.” About GeneThera, Inc. GeneThera is a biotechnology company developing molecular robotic/AI diagnostics and therapeutics in an effort to control and eradicate zoonotic diseases. GeneThera developed molecular assays for BSE and Mycobacterium Avium Paratuberculosis (MAP). MAP is an infectious organism causing Paratuberculosis in dairy cows that is also linked to Crohn’s Disease in humans. We utilize these technologies to minimize the spread of animal infectious organisms such as SARS-CoV-2 to humans. Management and prevention of zoonotic diseases is crucial to human and animal health on a global scale. This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release. For further information please contact: Tony Milici MD, Ph.D. GeneThera Inc. 720 587-5100